business
Vitroscope raises $7M to turn living human tissue into a new source of drug discovery data
Vitroscope raises $7 million, including a $5 million seed round, to turn living human tissue into drug discovery data
Key points
- Vitroscope's $7 million comprises a $5 million seed round and $2 million in non-dilutive funding.
- Cerberus Ventures and YZR Capital co-led the seed round; Arcas Ventures, Golden Egg Check and Devico Invest also participated.
- The biotech develops perfusion platforms to study immune activity, treatment responses and disease mechanisms in real time.
Why it matters. The round funds a company whose perfusion platforms study living tissue in real time, positioning them as a new source of drug discovery data.
Vitroscope, a biotech company, has raised $7 million, made up of a $5 million seed round and $2 million in non-dilutive funding. Cerberus Ventures and YZR Capital co-led the seed round, with participation from Arcas Ventures, Golden Egg Check and Devico Invest, plus angel investors including Carles Reina. The company develops perfusion platforms that study immune activity, treatment responses and disease mechanisms in real time.
Latest updates
Vitroscope raises $7M to turn living human tissue into a new source of drug discovery data
Vitroscope, a biotech company developing perfusion platforms to study immune activity, treatment responses and disease mechanisms in real time, has raised $7 million, comprising a $5 million seed roun... Vitroscope, a biotech company developing perfusion platforms to study immune activity, treatment responses and disease mechanisms in real time, has raised $7 million, comprising a $5 million seed round and $2 million in non-dilutive funding. Cerberus Ventures and YZR Capital co-led the seed round, with participation from Arcas Ventures, Golden Egg Check, Devico Invest and angel investors, including Carles Reina, Fàtima….